- Home
- PBFS vs ATYR Comparison
PBFS vs ATYR Comparison
Compare PBFS & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- ATYR
- Stock Information
- Founded
- PBFS 1889
- ATYR 2005
- Country
- PBFS United States
- ATYR United States
- Employees
- PBFS N/A
- ATYR N/A
- Industry
- PBFS Banks
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PBFS Finance
- ATYR Health Care
- Exchange
- PBFS Nasdaq
- ATYR Nasdaq
- Market Cap
- PBFS 309.6M
- ATYR 330.7M
- IPO Year
- PBFS N/A
- ATYR 2015
- Fundamental
- Price
- PBFS $12.00
- ATYR $3.97
- Analyst Decision
- PBFS
- ATYR Strong Buy
- Analyst Count
- PBFS 0
- ATYR 6
- Target Price
- PBFS N/A
- ATYR $18.60
- AVG Volume (30 Days)
- PBFS 26.5K
- ATYR 2.0M
- Earning Date
- PBFS 05-12-2025
- ATYR 03-13-2025
- Dividend Yield
- PBFS N/A
- ATYR N/A
- EPS Growth
- PBFS 6.93
- ATYR N/A
- EPS
- PBFS 0.76
- ATYR N/A
- Revenue
- PBFS $88,118,000.00
- ATYR $235,000.00
- Revenue This Year
- PBFS N/A
- ATYR $1,387.23
- Revenue Next Year
- PBFS N/A
- ATYR $873.22
- P/E Ratio
- PBFS $15.79
- ATYR N/A
- Revenue Growth
- PBFS 10.09
- ATYR N/A
- 52 Week Low
- PBFS $8.76
- ATYR $1.42
- 52 Week High
- PBFS $12.20
- ATYR $4.66
- Technical
- Relative Strength Index (RSI)
- PBFS 58.29
- ATYR 56.81
- Support Level
- PBFS $11.76
- ATYR $2.98
- Resistance Level
- PBFS $12.20
- ATYR $3.73
- Average True Range (ATR)
- PBFS 0.25
- ATYR 0.40
- MACD
- PBFS -0.01
- ATYR 0.04
- Stochastic Oscillator
- PBFS 66.10
- ATYR 80.32
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.